Introduction
Keloids are treated with a combination of medical and procedural approaches, most often including corticosteroid injections, silicone-based therapies, pressure treatment, cryotherapy, laser therapy, surgical removal in selected cases, and, in more resistant lesions, radiation or newer intralesional agents. These treatments are used because keloids are not simply scars that look different; they reflect an abnormal wound-healing response in which fibroblasts remain overactive, collagen production is excessive, and the normal signals that stop scar growth are impaired.
The overall aim of treatment is to reduce the raised, firm tissue, ease symptoms such as itching or pain, prevent further enlargement, and lower the chance that the lesion will return after treatment. Because keloids are driven by a persistent biologic process rather than a single isolated lesion, the most effective strategies are often those that suppress abnormal collagen deposition and remodel the scar over time.
Understanding the Treatment Goals
The main goals in treating keloid are to control the underlying excess scar formation and improve the physical and symptomatic effects of the lesion. A keloid may cause itching, tenderness, burning, restricted movement if it crosses a joint, or cosmetic distortion. Treatment therefore aims both at symptom relief and at changing the tissue behavior that keeps the scar growing beyond the original wound boundary.
Biologically, keloid tissue is characterized by prolonged inflammatory signaling, increased transforming growth factor beta activity, increased fibroblast proliferation, and high collagen deposition, especially type I and type III collagen. Treatment decisions are guided by the need to reduce these processes while also addressing the mechanical effects of the scar. In some patients, the priority is flattening and softening the lesion; in others, the key goal is preventing regrowth after a procedure or limiting recurrence after an injury.
Another important treatment goal is to avoid creating additional trauma that could stimulate more scar formation. This is why keloid management often relies on gradual suppression of the tissue response rather than aggressive removal alone. The treatment strategy is usually selected according to lesion size, location, symptoms, and previous response, because each of these factors reflects how active and resilient the scar tissue is.
Common Medical Treatments
Intralesional corticosteroid injections are among the most widely used treatments for keloids. These injections place a steroid, commonly triamcinolone, directly into the scar tissue. Corticosteroids reduce inflammation, inhibit fibroblast activity, and decrease collagen synthesis. They also promote some collagen breakdown and can reduce the production of inflammatory mediators that keep the scar biologically active. Over time, the tissue often becomes flatter, softer, and less symptomatic. Their value lies in directly suppressing the cellular processes that drive continued overgrowth.
Silicone gel sheets or silicone gel are used to modify the local environment of the scar. Their exact mechanism is not fully defined, but they appear to reduce transepidermal water loss, improve hydration of the stratum corneum, and influence signaling in the healing tissue. This can reduce itch and erythema and may help limit further collagen accumulation. Silicone is typically used as a noninvasive method to influence the maturation phase of scar healing rather than to remove existing scar tissue.
Pressure therapy works by applying sustained external force to the scar, most commonly after surgery or in areas where compression can be maintained. The pressure reduces local blood flow, alters oxygen tension, and changes the mechanical environment that fibroblasts respond to. Because fibroblasts are sensitive to mechanical stress, sustained compression can decrease extracellular matrix production and slow the growth of the scar. This approach is especially useful when the goal is to limit recurrence after another procedure.
Cryotherapy uses controlled freezing to injure the abnormal scar tissue. The cold causes cellular damage, vascular stasis, and subsequent tissue necrosis, which can reduce bulk and soften the lesion. In intralesional cryotherapy, the freezing effect is delivered more directly into the scar, allowing a deeper impact on dense keloid tissue. The biologic rationale is that destroying part of the overactive scar reduces the population of cells responsible for persistent collagen deposition.
Laser therapy, including pulsed dye laser and other resurfacing lasers, is used to alter both the vascular and structural features of keloid tissue. Pulsed dye laser targets hemoglobin in abnormal blood vessels, reducing erythema and potentially decreasing inflammatory support for the lesion. Other laser types can remodel collagen by inducing controlled thermal injury, which triggers a more organized repair response. Laser treatment does not eliminate the underlying tendency to form keloids, but it can improve texture, color, and symptoms while modifying scar architecture.
Intralesional chemotherapy or antimetabolite injections, such as 5-fluorouracil, are used in some cases to suppress fibroblast proliferation. These agents interfere with DNA synthesis and cell division, which makes them effective at slowing the cellular expansion responsible for thick scar tissue. When combined with corticosteroids, they may have a stronger effect on flattening keloids than either treatment alone. Their use reflects the fact that keloid growth depends on a population of fibroblasts that remain excessively active.
Interferon injections have also been used in selected cases. Interferons can reduce collagen production and influence the signaling pathways that regulate fibroblast behavior. Their use is less common than corticosteroids or 5-fluorouracil, but they illustrate a more targeted attempt to alter the molecular activity of the scar.
Procedures or Interventions
Surgical excision is used when a keloid is large, functionally restrictive, or unresponsive to conservative treatment. The procedure removes the visible lesion, but surgery alone is not considered definitive therapy because the wound created by excision can itself trigger another keloid. This occurs because surgery reactivates the wound-healing cascade, which in susceptible individuals restarts excessive fibroblast activity and collagen deposition. For that reason, excision is usually paired with another treatment such as steroid injections, pressure therapy, silicone, or radiation.
Postoperative radiation therapy may be used after keloid excision to reduce recurrence. Radiation affects rapidly dividing cells and suppresses fibroblast proliferation in the early wound-healing period, when the risk of recurrent scar formation is highest. By limiting cellular replication and matrix production in the repaired site, radiation lowers the biologic drive for the scar to reform. It is generally reserved for refractory or recurrent lesions because it is aimed at preventing regrowth rather than simply improving appearance.
Combination procedures are common because keloids usually arise from multiple abnormal pathways at once. For example, excision may remove bulk, corticosteroids may suppress fibroblast activity, and pressure or silicone may help maintain a low-growth environment during healing. In practical terms, combined therapy addresses both the tissue already present and the biological signals that would otherwise rebuild it.
Supportive or Long-Term Management Approaches
Long-term management focuses on reducing the stimuli that keep the scar active and on observing the lesion for signs of renewed growth. Because keloids can remain biologically responsive for months or years, follow-up care is often as important as the initial procedure. Serial assessment allows treatment to be adjusted if the scar becomes redder, firmer, more raised, or more symptomatic, which usually indicates renewed fibroblast activity and collagen deposition.
Supportive approaches also include strategies that limit additional injury to the skin. Repeated trauma, tension across a wound, or persistent inflammation can reinforce the same signals that promote keloid formation. In anatomical areas with high mechanical stress, long-term control may depend on reducing stretch on the skin so that the wound does not repeatedly activate the repair cascade.
Some patients benefit from ongoing topical or intralesional therapy over time, rather than a single intervention. This reflects the chronic nature of the underlying biology. A keloid may appear clinically stable but still contain active fibroblasts and disordered extracellular matrix turnover. Continued management helps keep that activity suppressed and may prevent the scar from thickening again.
Factors That Influence Treatment Choices
Treatment selection depends heavily on the size, location, and maturity of the keloid. Small or newly forming lesions are often more responsive to injections or silicone-based approaches because the fibrotic process may still be modifiable. Larger, older, or repeatedly recurrent keloids often have a more established collagen network and may require combination therapy or procedural intervention.
Location matters because some areas of the body are exposed to more tension or movement, and these mechanical forces can worsen recurrence. Keloids on the chest, shoulders, jawline, or earlobes often behave differently because the local biomechanical environment affects fibroblast signaling and wound contraction. Treatment plans are therefore influenced by how much mechanical stress the tissue experiences during healing.
Age and general health can also influence management. Younger individuals may have more active wound-healing responses, which can increase recurrence risk. Certain medical conditions, such as inflammatory skin disease or disorders that impair normal healing, can also alter how aggressively a lesion behaves. Previous treatment response is another major factor. If a lesion has recurred after excision alone, that history suggests that surgery by itself does not sufficiently suppress the underlying biology, so a more layered approach is usually chosen.
Potential Risks or Limitations of Treatment
Most keloid treatments have limitations because none fully correct the biological tendency to form excessive scar tissue. A treatment may flatten the lesion without eliminating the abnormal signaling that caused it, so recurrence remains possible. This is especially true after surgery, where the new wound can reactivate the same fibrotic pathway that created the original scar.
Corticosteroid injections can cause local skin atrophy, pigment change, small surface blood vessels, or discomfort at the injection site. These effects arise because steroids not only reduce fibroblast activity but also suppress normal tissue repair processes. When the dose or exposure is high, the surrounding skin may become thinner or less robust.
Cryotherapy may produce blistering, pain, hypopigmentation, or delayed healing because freezing damages not only the keloid tissue but also nearby normal tissue. Radiation, while useful for reducing recurrence after excision, carries concern about cumulative tissue effects and is therefore reserved for selected cases. Laser therapy may improve color and texture without fully controlling the biologic activity of the scar, and repeated sessions are often needed.
Another limitation is that keloids are variable in how they respond. One lesion may soften readily with injection therapy, while another remains resistant because of differences in fibroblast behavior, collagen density, or local inflammation. This variability reflects the underlying biology of the condition and is one reason treatment often requires a sequence of interventions rather than a single definitive method.
Conclusion
Keloid treatment is aimed at controlling an abnormal wound-healing process marked by persistent fibroblast activity, excess collagen production, and prolonged tissue growth beyond the original injury site. The main treatments include corticosteroid injections, silicone, pressure therapy, cryotherapy, laser therapy, antimetabolite injections, surgery in selected cases, and sometimes radiation after excision. Each approach works by reducing inflammation, suppressing fibroblasts, altering local tissue mechanics, or destroying part of the overgrown scar.
Because keloids are biologically active scars rather than static marks, treatment is best understood as an effort to modify the tissue environment and interrupt the processes that keep the scar enlarging. The choice of therapy depends on lesion characteristics, recurrence history, and the balance between effectiveness and procedural risk. In this way, keloid management is less about removing scar tissue alone and more about controlling the underlying physiology that drives it.